Targeted Degradation of KAT6A: Expanding the Therapeutic Frontier of Epigenetic Drug Discovery

Targeted protein degradation continues to reshape modern drug discovery by extending therapeutic intervention beyond conventional inhibition. A recent patent application discloses KAT6 degraders that selectively degrade KAT6A, an oncogenic histone acetyltransferase implicated in multiple malignancies. These degraders demonstrate potent target removal, durable pathway suppression, and enhanced antiproliferative activity, highlighting protein degradation as a promising strategy for epigenetic cancer therapy.